Stem Cell Clinic

Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells – BioSpace

By Induced Pluripotent Stem Cells

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells.

The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN gene-edited iPSC-derived NK products (partnership products). Cellectis will also receive single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds.

We are excited to collaborate with Cellectis, a gene-editing pioneer and leader in the development of gene-edited allogeneic cancer therapies, to further accelerate Cytovias NK cell programs, said Dr. Daniel Teper, Chairman & CEO of Cytovia Therapeutics. Cellectis has a deep understanding and proven expertise in gene-edited cell therapies, and their gene editing technology, TALEN, will yield NK and CAR-NK treatments with improved potency, persistence, and safety for a variety of cancers, including solid tumors. We look forward to leveraging Cellectis insights and experience to help move Cytovias CAR-NKs into clinical trials by 2022.

Cellectis will develop custom TALEN, which Cytovia will use to edit iPSCs. Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license to its TALEN gene-editing technology, enabling Cytovia to modify NK cells addressing multiple gene targets for therapeutic use in several cancer indications.

We are thrilled to partner with Cytovia, a pioneer in the development of NK cells derived from iPSCs, said Dr. Andr Choulika, CEO of Cellectis. We are looking forward to this collaboration and the opportunity to further expand the potency of our proprietary TALEN gene-editing technology to iPSCs and CAR-NKs. Down the road, this collaboration should allow for NK cell therapies to be made available to cancer patients, which is very much in line with Cellectis mission to provide life-saving product candidates to address unmet patient needs in this field.

About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit http://www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN is a registered trademark owned by Cellectis.

About Cytovia Therapeutics Cytovia Therapeutics Inc. is a biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company is establishing R&D and GMP manufacturing operations in the greater Boston area and partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, INSERM, and CytoImmune Therapeutics. Learn more at http://www.cytoviatx.com and follow Cytovia Therapeutics on Social Media (Facebook, LinkedIn, Twitter, and Youtube).

About Gene-Edited, iPSC-derived NK Cells Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). In addition, CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the induced pluripotent stem cell (iPSC)-derived CAR-NKs, an innovative technology, allow large quantities of true off-the-shelf, homogeneous genetically modified CAR NK cells to be produced from a gene-edited iPSC master cell bank, and thus hold promise to expand access to cell therapy for many patients.

For further information, please contact:

Cellectis Media contacts: Margaret Gandolfo, Communications Manager, 646-628-0300, margaret.gandolfo@cellectis.com Conor McGoldrick, Zeno Group, Assistant Account Executive, 914-355-0927, Conor.Mcgoldrick@zenogroup.com

Cellectis IR contact: Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Cytovia Investor Relations contact: Anna Baran-Djokovic VP of Investor Relations 646-355-1787 anna@cytoviatx.com

Cytovia Media contact: Chris Maggos LifeSci Advisors +41 79 367 6254 chris@lifesciadvisors.com

Disclaimer

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, believe, expected, forward looking, promising and will, or the negative of these and similar expressions. These forward-looking statements, are based on our managements current expectations and assumptions and on information currently available to management. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

PDF available at: http://ml.globenewswire.com/Resource/Download/c6bbee7d-f56e-400c-a6a4-28586a9e4851

Read more:
Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells - BioSpace

Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding…

By Induced Pluripotent Stem Cells

The Induced Pluripotent Stem Cells Market grew in 2019, as compared to 2018, according to our report, Induced Pluripotent Stem Cells Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Induced Pluripotent Stem Cells Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025.

Deep analysis about Induced Pluripotent Stem Cells Market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Induced Pluripotent Stem Cells Market

Get a Sample Copy of the Report at: https://i2iresearch.com/download-sample/?id=8913

The Induced Pluripotent Stem Cells Market is analysed based on product types, major applications and key players

Key product type: Hepatocytes Fibroblasts Keratinocytes Amniotic Cells Others

Key applications: Academic Research Drug Development And Discovery Toxicity Screening Regenerative Medicine

Key players or companies covered are: Fujifilm Holding Corporation Astellas Pharma Fate Therapeutics Bristol-Myers Squibb Company ViaCyte Celgene Corporation Aastrom Biosciences Acelity Holdings StemCells Japan Tissue Engineering Organogenesis

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/need-customization/?id=8913

Key questions answered in the report: 1. What is the current size of the Induced Pluripotent Stem Cells Market, at a global, regional & country level? 2. How is the market segmented, who are the key end user segments? 3. What are the key drivers, challenges & trends that is likely to impact businesses in the Induced Pluripotent Stem Cells Market? 4. What is the likely market forecast & how will be Induced Pluripotent Stem Cells Market impacted? 5. What is the competitive landscape, who are the key players? 6. What are some of the recent M&A, PE / VC deals that have happened in the Induced Pluripotent Stem Cells Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us: i2iResearch info to intelligence Locational Office: *India, *United States, *Germany Email: [emailprotected] Toll-free: +1-800-419-8865 | Phone: +91 98801 53667Induced Pluripotent Stem Cells, Induced Pluripotent Stem Cells Market, Induced Pluripotent Stem Cells Market Size, Induced Pluripotent Stem Cells Market Growth, Induced Pluripotent Stem Cells Market forecast, Induced Pluripotent Stem Cells Industry, Induced Pluripotent Stem Cells Market Overview, Induced Pluripotent Stem Cells Market Share, Induced Pluripotent Stem Cells Trends, Induced Pluripotent Stem Cells Market Analysis, Induced Pluripotent Stem Cells Market Revenue, North America Induced Pluripotent Stem Cells Market, Europe Induced Pluripotent Stem Cells Market, Asia Pacific Induced Pluripotent Stem Cells Market, Middle East & Africa Induced Pluripotent Stem Cells Market

https://neighborwebsj.com/

Excerpt from:
Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding...

Can we freeze them? Yes we can, says Nkarta – Vantage

By Induced Pluripotent Stem Cells

Paul Hastings, chief executive of Nkarta, is not shy about his companys achievement. We have mastered cryopreservation, he tells Evaluate Vantage.

And with that the company might have solved the biggest problem to have held back development of NK cell therapeutics: normally the cells cannot be frozen without risking changing their phenotype. Nkarta also reckons to have cracked another problem, transducing NK cells with a retrovirus, and its optimism matches the market mood of resurgent enthusiasm for these therapies.

That enthusiasm for NK cells took off at last years Ash meeting, and Nkarta, along with Gamida Cell, Fate Therapeutics and Nantkwest, celebrated surging stock prices. Remarkably, Nkarta presented no clinical data at the conference, though it has since started trials of its first Car-NK therapy, NKX101, targeting NKG2D ligands.

What do we want?

One of the things we defined right up front was what we wanted from a product, Mr Hastings says. Until we got that we werent going to try and move these things into the clinic.

For Nkarta a product must be off the shelf and cryopreserved though just how this is achieved is a proprietary secret and it must come in a vial, not a bag, so it can be multiple-dosed easily. The aim is to ship Car-NK cells just like an antibody directly to a doctor.

Thus affordability, a thorny issue for cell therapies, is at the core of Nkartas thinking. Mr Hastings reckons cost of manufacturing can be limited to $2,000 per vial of a billion NK cells; and, as each dosing cycle comprises three lots of 100 million cells, each vial could give up to three cycles.

As for supply, Nkarta sources NK cells from healthy donors, in contrast to Fate, which uses induced pluripotent stem cells (iPSCs). Mr Hastings says each healthy donor can yield 500 doses, and manufacturing, including standard viral transduction, takes 14 days, with the inclusion of membrane-bound IL-15 improving persistence and reducing exhaustion, ensuring that cells are maximally potent when delivered.

TheiPSC approach is seen as more advanced, but iscomplex asdesired characteristics need to be engineered in. Mr Hastings says with donor-derived cells you start with a large number of cells, and theyre actually NK cells, though he does not rule out looking at iPSCs in future.

Were all placing bets, and this is our bet, adds James Trager, Nkartas chief scientific officer. And he denies that donor-derived cells lack flexibility, saying the donor pool is very diverse: There are a fair number of donors walking around who have NK cells with pretty exceptional properties.

For now, however, Nkarta is not looking at donors with NK cells expressing high-affinity CD16; Fate, for instance, engineers this into most of its projects to improve antibody-dependent killing.

Clinical data

Investors do not have long to wait for the first evidence of NKX101s clinical activity. Mr Hastings says Nkarta expects interim results from a handful of patients at a medical meeting not by press release towards the end of 2021.

And an IND filing for the groups second asset, a CD19-targeting Car-NK coded NKX019, is due in the current quarter. This gives Nkartas pipeline a mix of proven (CD19) and high-risk (NKG2D ligands) approaches, and final proof-of-concept data for both are due in the first half of 2023; current cash, meanwhile, takes Nkarta to the second half of that year.

On a design level both therapies differ from current Car-T approaches in using as the co-stimulatory domain not 4-1BB or CD28 but Ox40, which Mr Trager says gives NK cells the best serial killing activity.

Even though the CD19 space is extremely crowded, unlike many other cell therapy players Nkarta is not using a CD19 approach just to test its tech. We absolutely believe that a CD19 programme thats allogeneic, cryopreserved in a vial is going to be very competitive, stresses Mr Hastings.

And the groups next project will target solid tumours, but for now remains under wraps. The way well disclose targets is when we have a clinical candidate, says the chief exec.

See original here:
Can we freeze them? Yes we can, says Nkarta - Vantage

Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas…

By Induced Pluripotent Stem Cells

A consistent statistical surveying report like this Induced Pluripotent report stretches out your reach to the achievement in your business. All the information and measurement remembered for the report is supported up by notable investigation devices which incorporate SWOT examination and Porters Five Forces investigation. Statistical surveying contemplates did in this report are chivalrous which help organizations to take better choices and create predominant methodologies about creation, advertising, deals and advancement. Market definition, market division, key improvements in the market, serious investigation and examination approach are the significant section of this Induced Pluripotent market report which are again explained accurately and explicitly.

Induced Pluripotent statistical surveying report has been formed with most up-to-date insight and examination to give greatest advantages to the healthcare business. The Induced Pluripotent market report features the worldwide key makers to characterize, depict and break down the market rivalry scene through SWOT investigation. A variety of goals of the showcasing research has been considered to produce this best statistical surveying report. The market information introduced in the report assists with perceiving diverse market openings present globally. Serious investigation acted in this Induced Pluripotent report makes you mindful about the moves of the vital participants in the market, for example, new item dispatches, extensions, arrangements, joint ventures, associations, and acquisitions.

Few of the major competitors currently working in the induced pluripotent market areBristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Objective of the Report

Market Drivers

Market Restraints

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-induced-pluripotent-market

Key Developments in the Market:

Segmentation: Global Induced Pluripotent Market

By Product Category

By Cell Type

By Application

By End-User

By Geography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-market

Potentials held by the report

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:Corporatesales@databridgemarketresearch.com

Read this article:
Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas...

Induced Pluripotent Stem Cells Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis…

By Induced Pluripotent Stem Cells

The latest report is the most recent study that offers 360 coverage of the Induced Pluripotent Stem Cells industry that has been facing the brunt of the adverse economic impact of the COVID-19 outbreak since the beginning of this year.

Top Companies Profiled in this Report are:

Thermo Fisher Scientific, Allele Biotechnology and Pharmaceuticals Inc., ABM (Applied Biological Materials Inc.), Addgene, Axol Bioscience, Cell Signaling Technology, Bluerock Therapeutics, Alstem LLC, Applied Stemcell Inc., ATCC, Creative Bioarray, Bristol-Myers Squibb, Bio-Techne, Reprocell Group Co., Primorigen Biosciences, ID Pharma Co. Ltd., Megakaryon Corp., FUJIFILM Cellular Dynamics, Inc., Waisman Biomanufacturing, Roslin Cell Sciences, Opsis Therapeutics, Corning Life Sciences, Fate Therapeutics, Genecopoeia, Gentarget Inc., Viacyte Inc., Ncardia, Invivogen, Lonza Group Ltd., Plasticell Ltd., Stemcell Technologies, Newcells Biotech, Orig3N Inc., Peprotech, Promega Corp., Promocell Gmbh, Qiagen N.V., System Biosciences Inc., Reprocell Inc., Sciencell Research Laboratories, MilliporeSigma, and Takara Bio Usa Inc.

Overview of the Induced Pluripotent Stem Cells report:

The Induced Pluripotent Stem Cells market has been broadly segmented to aid readers in gaining a more in-depth understanding of different facets and attributes of the market. The market scope for the new entrants and established companies has been assessed using various analytical tools, including the SWOT analysis, investment assessment, and Porters Five Forces analysis. Furthermore, into the study, the authors of the report have evaluated the financial standing of leading companies operating in the industry. They have provided crucial information on gross profits, revenue shares, sales volume, manufacturing costs, individual growth rate, and numerous other financial ratios of these competitors.

Click to get Discount on this Induced Pluripotent Stem Cells Market [emailprotected] https://www.reportsanddata.com/discount-enquiry-form/3551

Segmentation Analysis

The report gives an extensive analysis of various segments of the market by studying the product range, applications, major regions, and leading companies in the industry. Additionally, the report also dedicates an individual section to give a detailed analysis of the manufacturing process, which includes information collected through both primary and secondary sources of data collection. The primary source of data collection contains interviews of industry experts who offer accurate insights into the future market scenario.

Derived Cell Type Outlook (Revenue in USD Million; 20172027)

Application Outlook (Revenue in USD Million; 20172027)

End-User Outlook (Revenue in USD Million; 20172027)

Induced Pluripotent Stem Cellsmarket segmentation by geographical regions, the report has analysed the following regions-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Download Summary[Free Extract]@ https://www.reportsanddata.com/sample-enquiry-form/3551

The Induced Pluripotent Stem Cells Market Research/Analysis Report addresses the following questions:

WhichManufacturing Technologiesare prevalent in the production of Induced Pluripotent Stem Cells? What are the Recent Developmentsrelating to that technology? WhichTrendsare responsible for these developments?

Who are the leading vendors in the GlobalInduced Pluripotent Stem Cells Market? What are their individual market standing and contact information?

What is the current industrial scenario of the Global Induced Pluripotent Stem Cells Market? What were the Value, Volume, Production Capacity, Cost, and Profit Margin of the overall market?

What is the outcome of the competitive analysis on the Induced Pluripotent Stem Cells Market both in terms of companies and regions? What is the market assessment for the Induced Pluripotent Stem Cells Market as per the market segmented into types and applications?

Thank you for reading our report. Customization of the report is available as per client requirements. Kindly get in touch with us to know more about the report.

Explore our related report :

Hemostasis Analyzers Market Growth

Surgical Instruments Market Share

Tele-Intensive Care Unit (ICU) Market Size

Dimethylformamide (DMF) Market Trends

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Get Insights into Induced Pluripotent Stem Cells Market [emailprotected] https://www.reportsanddata.com/report-detail/induced-pluripotent-stem-cells-market

Contact Us:

John W

Head of Business Development

Direct Line: +1-212-710-1370

Explore our related report from different Publications:

Cosmetic Chemicals Industry Growth Rate

Cosmetic Chemicals Industry Revenues

Cosmetic Chemicals Market Projections

Cosmetic Chemicals Market Revenue

Cosmetic Chemicals Industry Sales

Cosmetic Chemicals Sales Statistics

Cosmetic Chemicals Industry Annual Sales

Cosmetic Chemicals Industry Growth Rate

Cosmetic Chemicals Industry Revenues

Cosmetic Chemicals Market Projections

Cosmetic Chemicals Industry Growth Rate

Cosmetic Chemicals Industry Revenues

Cosmetic Chemicals Market Projections

Cosmetic Chemicals Market Revenue

Cosmetic Chemicals Industry Sales

Continued here:
Induced Pluripotent Stem Cells Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis...

Winter Weather Impacting Blood and Platelet Donations – Milwaukee Community Journal

By Stem Cell Medical Center

Versiti Blood Center of Wisconsin calling on donors to help as supplies drop;

blood types O-negative, O-positive most needed

Milwaukee Feb. 16, 2021 With winter storm warnings and advisories in place across much of the Midwest, Versiti Blood Centers is grappling with low and quickly dwindling supplies of blood and platelet donations.

The unrelenting winter weather is taking its toll on the blood supply across the Midwest, said Dr. Dan Waxman, vice president of transfusion medicine and senior medical director at Versiti. Supplies of some blood types, including O-negative and O-positive, are reaching critically low levels, with less than a days supply of life-saving blood on shelves to supply Versitis hospital partners across Wisconsin, Indiana, Illinois, Michigan and Ohio. We simply do not have the three-day supply of blood that we need.

The winter weather advisories and warnings are adding to the ongoing blood collection challenges that centers have been facing during COVID due to remote work and schooling. In the past year, Versiti has experienced a 47% decrease in mobile drive collections at business and schools.

Platelets which are used to help cancer patients, trauma survivors and premature babies are only viable for five to seven days outside the body, creating a constant and ongoing need for donations. Like blood, platelets cant be manufactured, so Versiti needs volunteer donors to roll up their sleeves.

We are asking the community to step forward and help, said Dr. Waxman. Unfortunately, we cant wait a week until a cold snap subsides to provide these life-saving gifts. For these patients who rely on us, they need our help today, regardless of the weather forecast.

O-negative and O-positive blood donors are most needed now. O-negative and O-positive blood is the universal blood type, meaning donations can be transfused to all patients, including trauma victims, cancer patients and those undergoing surgery.

Badgers are needed to extend the generous gift of life to neighbors who need help and to donate blood at a Versiti Blood Center of Wisconsin donor center nearest them:

Wisconsin residents can also make an appointment to donate at a local community blood drive in their area. Times, dates and locations of upcoming local drives can be found online https://donate.wisconsin.versiti.org. Interested donors should click the Schedule to Donate tab to find the nearest drive to them.

To help ensure donor safety, everyone entering Versiti facilities must wear a mask and have their temperature taken. All Versiti donation locations are practicing social distancing and closely adhering to CDC recommendations and cleaning protocols.

Donating blood takes about an hour with the actual donation taking 10-15 minutes. Anyone age 17 or older in good health who meets eligibility requirements is encouraged to give. Parental consent is required for donors age 16 to donate blood. Donors should bring a photo ID that includes their birth date.

Appointments are encouraged at any of Versitis Wisconsin donor centers or at any local community blood drive. Walk-ins are always welcome. To schedule an appointment to donate blood, call 1-877-BE-A-HERO or visit Versiti online at versiti.org/Wisconsin.

# # #

About Versiti Blood Center of Wisconsin

Versiti Blood Center of Wisconsin is a not-for-profit organization headquartered in Milwaukee that specializes in blood services, esoteric diagnostic testing, organ, tissue and stem cell

donation, medical services and leading-edge research. We advance patient care by delivering life-saving products and services. For more information, visit versiti.org/Wisconsin.

Here is the original post:
Winter Weather Impacting Blood and Platelet Donations - Milwaukee Community Journal

Joshua Shirk continues to fight the odds; mom says God placed people where they needed to be to help him – Keyser Mineral Daily News Tribune

By Stem Cell Medical Center

Mineral Daily News-Tribune

a

By Barbara High

bhigh@newstribune.info

Tribune Staff Writer

KEYSER - Monica Shirk is still holding fast to her faith - a faith that has helped see her and her family through many obstacles over what will soon be a year.

May 17, 2020, started out as any other day for the Shirks; the sun was shining and their family was together. But it would soon become the day that would forever change their lives with an event that would touch and bring together a community.

The family was out on the river in their kayaks that day. Monicas 8-year-old son Joshua was in his own kayak and was tethered to a family member. When they came upon a felled tree with a large root system in the river, however, Joshua was swept under,, becoming entangled by his life jacket in the roots. Two paramedics happened to be fishing nearby, and came to the familys aid. Approximately five to ten minutes later, Joshua was pulled from the river with no pulse. After 40 minutes of lifesaving efforts, however, Joshua once again had a pulse. Monica says she believes everything was laid out in a grand design, from those with them who pulled Joshua from the river, to the paramedics fishing nearby who werent even supposed to be on the river that day.

For Monica it was simple, God had put the right people in Joshuas path that day and has continued to do so every day since. She said that was the reason that Joshua, the boy who spent 40 minutes without life, was able to leave the hospital 30 days after entering. She also says that God continues to do so with everyone who has helped treat Joshua in the last ten months. Treatments that she says have made all the difference in Joshuas recovery.

Joshua left Ruby Memorial just 30 days after being admitted, and then spent a short time in a rehabilitation center until the Shirks were finally able to return home. That time home was short lived, however, because the path for recovery for Joshua was just beginning.

Joshua was released from the rehab center on Sept. 16, and two days later we were on our way to New Orleans, said Monica. There, they would stay for nine weeks as Joshua underwent hyperbaric oxygen therapy. Joshua would complete 41 dives in a chamber over the next nine weeks. The dives cost $12,000 for 40.

Monica said Joshua was able to have his dad in the chambers with him during the dives, when Joshua would be put in a pressurized chamber and be given different doses of pressurized air and oxygen.

The dives are designed to infiltrate the body with pure oxygenated air. Once put into the body, the air finds areas of inflammation and delivers oxygen-enriched blood, allowing the area to heal itself. For Joshua, those areas would include his brain, which had suffered swelling after the incident and is still inflamed.

Joshua will need to complete many more dives in the future. The family recently purchased a chamber for Joshua to use at home at a cost of $26,000, which was only made possible by donations they had received from a lot of wonderful people.

Monica said the cost of the dives, plus lodging and food in New Orleans, was more than the family could handle. To rent a place for a month was over $4,000 and the dives were $12,000, and that didnt include food, she said. With purchasing their own chamber, Joshua will be able to continue his dives without delay.

Joshuas doctor, Dr. Harch, will fly to the family to set up Joshuas chamber and train his family and then will oversee his care from New Orleans.

During their time in New Orleans the family was also steered towards exosmoes infusions, and with the help of his doctor, that would be the next course for the youngster.

We met other families of non-fatal drowning victims and spoke to them and they had done them, so with research and talking to the doctor, we decided to go that route, she said.

Also while in New Orleans, the family learned they would have to make the trip again.

Exosmose infusions, or Red Bull for stem cells, as his dad calls them, do kind of the same thing as his previous treatment. Joshua was injected with a tiny valve of exosmose, and although it was small, it contained about 40 billion healthy exosmoses. Once introduced to the body, they too travel to the areas of inflammation and empower them with super foods enriched with nutrients to wake up cells and tell them to work again.

Joshua also recently traveled to Arizona to undertake some stem cell therapy. There, doctors extract some fat from him after numbing him really good, in a similar procedure as liposuction. They put the specimen under a slide to check if they are rich in cells. Joshuas fat had so many healthy cells that the computer couldnt count the number and they had to wipe off the slide and put another sample back on it, said Monica.

After the fat sample is taken, it is skinned so they can separate the cells. The stem cells are then given back to Joshua. Part of the cells are given to him nasally as a mist. By doing this, the stem cells are able to cross the blood brain barrier and immediately start to work. The remainder of the stem cells are then injected at the top of the tail bone at the base of the spinal cord. There they form a sack and the excess will release from the sack and travel up the spinal column into the brain.They also begin to break off and reproduce. They stimulate the areas of inflammation and damage, which helps to get them to fire again.

Monica said the results of this treatment will become apparent after six months.

You hear people say the brain dies during times of lack of oxygen, said Monica. God in fact puts in a safeguard switch that flips to hibernation, or shuts down, if you will. Everything were doing is to shock his brain in a way to wake it back up and turn it on; to tell it to wake up and do its job.

Besides the special treatments, Joshua is also doing regular physical therapy, preparing to start occupational therapy, and speech. He is doing acupuncture as well, to help release the energy to allow the body to heal itself.The micro trauma that the needles cause sends a message of damage to the body and it releases healing properties to that area.

Everything we have done so far is using his own body to try and heal itself, said Monica. Everything we have used has been his, with the exception of the exosmose.

As far as improvements in Joshua, his mom said those have been great. Its the difference between night and day, she says. It was harder for me to see the subtle changes. I am with him 24 hours a day, but when I see the old videos, it is like, wow!

Monica says you can see the difference in her sons eyes, His pupillary responses are better and he can track better, she said. She also says his tone is better and he is so close to being able to hold his own head up.

He can retract his legs now, where before he could only extend. Plus she says there is improvement in his response time. Before, when you gave him a command, there was a larger delay in the time between when you told him to kick his legs and when he would kick his legs, she explained. That delay has gotten shorter as his brain is beginning to send messages faster.

He has also begun to do a gait trainer, which is like a walker.

Yet those are not even his biggest improvements.

Joshua started talking, Monica said. He was recently heard saying on a Facebook video while having muscle spasms, It hurts.

Hearing Joshuas voice again was music to his mothers ears. I posted the video of him talking and within hours it had 3,700 views. She sent it to her husband and told him 3,000 was other people rejoicing, and 700 was how many times she had probably watched it.

I watched it over and over again, she said. Joshua tries to talk more and more; he is always making sounds, according to his mom.

His mom says she is able to hold strong for her son because of her faith. I am doing good, she said. It was hard after coming home for the first time since the accident and having to leave just two days later. When we got home, it was also difficult to see all the reminders of Joshua from before the accident, like his medals and stuff from sports, cause he was such an athlete. I saw all this stuff of the used to be, she said.

For his mom though, it is all a matter of time. I know he will get better, this is just what is for now, this is not what is forever, she said.

Monica sees this as a marathon, not a sprint. He is not a writer, he is a fighter and doesnt give up.

My faith is stronger than ever, I think it grows a little more each day.

She isnt going to lie; there are days that are hard. Im a mother who hurts to see her child hurting, but I dont doubt my son or my God!, she says.

I knew enough medically in the beginning to know that some things were impossible medically for him, but it had to be impossible for man not for God, and to give God the glory.

Monica says that things they didnt t think could be done are now being done for Joshua through God.

The human in her sometimes says he doesnt deserve this, then she remembers that Jesus didnt deserve what happened to him. Yet he took it and all my sins, she said.

Monica says she often puts herself into Marys shoes as a mother. She watched her son get crucified for the weight of the world and I realize that is one person hears Joshuas story and comes to Christ, then its worth it. Jjust one.

As far as the future, Monica say she does see a full recovery coming. Not that I have ever doubted Joshua or God, but I had my low point in the beginning. We were at one of his doctors visits in Morgantown in the beginning, and Joshua was just laying there like he did right after the accident. He wasnt moving or anything and I told God, I need you, she recalls.

She asked God to giver her a sign. If you are going to heal my son on this earth before you return, I need a big movement. Before the doctor comes in, I need a movement, she said. As she sat staring at her son in the moment, he had been laying there staring at the wall with his face away from her. While she asked God for that sign, Joshua turned his face and looked directly at her.

I immediately asked God, If that was you, I need another sign, and Joshua, who had turned back to the wall once again, turned back to look at me.

As the doctor knocked on the door to come in, Monica said Joshua began to kick and show off his movements.

Monica says that she doesnt believe in the word normal anymore, and she is fully believing that God will give Joshua a full recovery.

His baseline I believe is going to be bigger than normal, because he is going to be whole and telling people his story, she says. He will let people know that there is hope for whatever youre going through.

Monica says there was a prayer they use to say when Joshua would go and wrestle, When times get tough, we get tougher and never give up.

He has lived that out the whole time, she says.

Joshua will continue his physical therapy, acupuncture, and occupational therapy. He also has the goal of doing blocks of 40 dives in his chamber and then rest 30 days before repeating - all of which is made possible by donations to Joshuas trust fund. The community has come together to support Joshua during this horrendous time. There had been different fundraisers for him as well, and all of this is another example of how God has put people into Joshuas life at the perfect time.

Brain and spinal injured people are written off by insurances; they only want to medicate them, Monica says. We can only afford the thing we have by donations, she added. We are so very thankful for those who have helped.

If you would like to donate for medical care for Joshua or if you would like to follow his story, you can visit Facebook at Hes fighting, Were believing.

It is the hope of Joshuas family that everyone will see the strength of God, and witness first hand what happens when God shows up!

Read the original:
Joshua Shirk continues to fight the odds; mom says God placed people where they needed to be to help him - Keyser Mineral Daily News Tribune

Global Nerve Regeneration and Repair Market Estimated To Expand At A Robust CAGR By 2026||Boston Scientific Corporation, Alafair Biosciences,…

By Stem Cell Clinics

Global nerve regeneration and repair marketis registering a healthy CAGR of 12.95% in the forecast period of 2019-2026. This rise in the market value can be attributed to high incidences of nerve injuries globally. There are various technological advancement in the nerve repair technologies. There is a surge in the number of elderly population which is driving the market growth.

The market insights of the global Nerve Regeneration and Repair market report helps with the successful launch of new product. With this report, it gets easy to attain information about customer demographics which forms the core of any business. However, it is made sure that customer information is kept secret. The report efficiently gathers, analyzes and interprets information about a market, about a product or service to be offered for sale in that market. Potential customers for the product or service and their characteristics, spending habits, location and needs of the businesss target market, the industry as a whole, and the particular competitors faced are also studied in this Nerve Regeneration and Repair report.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nerve-regeneration-and-repair-market

Few of the major market competitors currently working in the global nerve regeneration and repair market areAxogen Corporation, Boston Scientific Corporation, Alafair Biosciences, Medtronic, Baxter, Checkpoint Surgical., Abbott, Integra LifeSciences Corporation, Nevro Corp., Orthomed (UK) Ltd, Collagen Matrix, Inc., Cyberonics, Inc., Stryker, Polyganics, LivaNova PLC, Nuvectra, NeuroPace, Inc., Allen Medical Systems, Inc., Autonomic Technologies, Inc., COOK BIOTECH, INC., Elkem ASA, GlaxoSmithKline plc, Helius Medical Technologies, The Magstim Company Ltd., TissueGen among others.

SEGMENTATION: GLOBAL NERVE REGENERATION AND REPAIRMARKET

By Product

(Neurostimulation and Neuromodulation Devices, Biomaterials),

Indication

(Failed Back Surgery Syndrome, Parkinsons disease, Urinary Incontinence, Epilepsy, Gastroparesis, Nerve Repair, Grafting),

Application

(Neurostimulation and Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting, Stem Cell Therapy),

End User

(Hospitals and Clinics, Ambulatory Surgical Centers),

Geography

(North America, South America, Europe, Asia-Pacific, Middle East & Africa)

Inquire Regarding This Reporthttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-nerve-regeneration-and-repair-market

Nerve Regeneration and Repair MarketScenario

According to Data Bridge Market Research the market for nerve regeneration and repair market is booming with the rising expenditure in the healthcare solutions. The climb in the ageing and maturing community globally and progress in the neurological dysfunctions encourages the business germination of nerve regeneration and repair market.

The rising demand of technological advancement and its integration with the current medical scenarios and services will shoot the growth of nerve regeneration and repair market.

Few of the restraints might hamper the market growth. Owing to the amount of cost and expenditure needed for the treatment this critical operation and to lack of trained and efficient staff to execute it will hinder the market growth in the anticipated time window. Also, major population is inclined towards the medicinal cure and therapy for nerve regeneration instead of surgical operation these factors will act as the restraint for the market development in the expected time frame of 2019 to 2026.

Now the question is which are the other regions intuitive is targeting? Data Bridge Market Research has forecasted a large growth North America, due to strong prevalence of healthcare facilities and developments or researches blooming day by day. This increment is followed by compensation feature to restore the occurred expenses which raises the chances of pocketing good revenue from nerve regeneration and repair market.

Table Of Content:

Part 01: Executive Summary Part 02: Scope Of The Report Part 03: Market Landscape

Part 04: Market Sizing

Part 05: Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape Part 08: Geographic Landscape

Part 09: Decision Framework Part 10: Drivers And Challenges

For More Insights Get Detailed TOC https://www.databridgemarketresearch.com/toc/?dbmr=global-nerve-regeneration-and-repair-market

Reasons to Purchase this Report

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:Corporatesales@databridgemarketresearch.com

Read this article:
Global Nerve Regeneration and Repair Market Estimated To Expand At A Robust CAGR By 2026||Boston Scientific Corporation, Alafair Biosciences,...

Adult T-Cell Leukemia/Lymphoma Treatment Market 2021 Present Scenario on Growth Analysis and High Demand to 2025 KSU | The Sentinel Newspaper – KSU |…

By Stem Cell Clinics

Recently Added a New Report by Big Market Research, the 2021 growth of Adult T-Cell Leukemia/Lymphoma Treatment will have significant change from previous year. By the most conservative estimates of global Adult T-Cell Leukemia/Lymphoma Treatment market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 115.1 million in 2019. Over the next five years the Adult T-Cell Leukemia/Lymphoma Treatment market will register a 3.4% CAGR in terms of revenue, the global market size will reach US$ 131.8 million by 2025.

2021studies theGlobal Adult T-Cell Leukemia/Lymphoma Treatment Marketwith many aspects of the industry like the market size, market status, market trends, and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Market segmentation by companies, region, and type forms an integral part of this report. Historical data available in the report supports the Adult T-Cell Leukemia/Lymphoma Treatment Market development on national, regional and international levels. This is an informative study covering the Adult T-Cell Leukemia/Lymphoma Treatment Market with in-depth analysis and portraying the current state of affairs in the industry.

Ask for a Sample PDF Copy of Adult T-Cell Leukemia/Lymphoma Treatment Market with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/4172080?utm_source=KSU&utm_medium=MWA

The core objective of the business intelligence report 2021 on theAdult T-Cell Leukemia/Lymphoma TreatmentMarket is to predict the industrys performance in the upcoming years and aid stakeholders in making well-informed decisions. The study stresses on the key trends and how those can be exploited to create future opportunities. The Adult T-Cell Leukemia/Lymphoma Treatment Market is also aids in developing counter approaches for major challenges faced by the industry. In the end, we examine some inside and outside variables that drive or breaking point of the Adult T-Cell Leukemia/Lymphoma Treatment Market.

NOTE:Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Market players have been discussed and profiles of leading players including Top Key Companies: Kyowa Kirin Daiichi Sankyo Seattle Genetics Inc. miRagen Therapeutics Celgene (Bristol-Myers Squibb) HUYA Bioscience International

Key questions answered in this report:

Talk to our Analyst / Ask for a discount on Adult T-Cell Leukemia/Lymphoma Treatment Market and Get More Information Related to This Report:https://www.bigmarketresearch.com/request-for-discount/4172080?utm_source=KSU&utm_medium=MWA

The Adult T-Cell Leukemia/Lymphoma Treatment Market is also characterized by a highly complex value chain involving product manufacturers, material suppliers, technology developers, and manufacturing equipment developers. Partnerships between research organizations and the industry players help in streamlining the path from the lab to commercialization. In order to also leverage the first mover benefit, companies need to collaborate with each other so as to develop products and technologies that are unique, innovative and cost effective.

How will this Market Intelligence Report Benefit You?

Get Access of Complete Copy of This Report and Avail Instant 10% Discount New Year Offerby Using Coupon Code [ORG123WA]:https://www.bigmarketresearch.com/checkout/sales/38016

The report includes the region-wise segmentation North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) of the market. In the regional segmentation, the regions dominating the Adult T-Cell Leukemia/Lymphoma Treatment market are included along with the regions where the growth of the market is slow.

By the product type, the Adult T-Cell Leukemia/Lymphoma Treatment Market is primarily split into 2020-2025: Chemotherapy Stem Cell Transplantation Targeted Therapy Others

By the end-users/application, the Adult T-Cell Leukemia/Lymphoma Treatment Market report covers the following segments 2020-2025: Hospitals Clinics Others

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Adult T-Cell Leukemia/Lymphoma Treatment market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, and growth drivers of by analyzing the historical overall data of the considered market segments.

You May Also Like Our Other Top Trending Reports:

For More Information Regarding Other Similar Trending Report Click on The Given Link:https://ksusentinel.com/2021/02/08/design-software-for-packaging-market-2021-global-industry-forecasts-analysis-competitive-landscape-and-key-regions-analysis/

Contact us: Mr. Abhishek Paliwal 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States Direct:+1-971-202-1575 Toll Free:+1-800-910-6452 E-mail:help@bigmarketresearch.com

See more here:
Adult T-Cell Leukemia/Lymphoma Treatment Market 2021 Present Scenario on Growth Analysis and High Demand to 2025 KSU | The Sentinel Newspaper - KSU |...

→←